Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Activation of autoreactive lymphocytes in the lung by radioresistant cells expressing a STING gain-of-function mutation
Kevin MingJie Gao, Kristy Chiang, Sharon Subramanian, Xihui Yin, Paul J. Utz, Kerstin Nündel, Kate A. Fitzgerald, Ann Marshak-Rothstein
Kevin MingJie Gao, Kristy Chiang, Sharon Subramanian, Xihui Yin, Paul J. Utz, Kerstin Nündel, Kate A. Fitzgerald, Ann Marshak-Rothstein
View: Text | PDF
Research Article Inflammation

Activation of autoreactive lymphocytes in the lung by radioresistant cells expressing a STING gain-of-function mutation

  • Text
  • PDF
Abstract

Gain-of-function mutations in the dsDNA sensing adaptor STING lead to a severe autoinflammatory syndrome known as STING-associated vasculopathy with onset in infancy (SAVI). Patients with SAVI develop interstitial lung disease (ILD) and produce autoantibodies that are commonly associated with systemic autoimmune diseases. Mice expressing the most common SAVI mutation, STING V154M (VM), similarly develop ILD but exhibit severe T and B cell lymphopenia and low serum Ig titers, and they lack autoantibodies. Importantly, lethally irradiated VM hosts reconstituted with WT stem cells (WT→VM) still develop ILD. In this study, we find that WT→VM chimeras had restored B cell function, produced autoantibodies, and thereby recapitulated the loss of tolerance seen in patients with SAVI. Lymphocytes derived from both WT and BCR or TCR transgenic (Tg) donors accumulated in the extravascular lung tissue of WT+Tg→VM mixed chimeras, but lymphocyte activation and germinal center formation required WT cells with a diverse repertoire. Furthermore, when T cells isolated from the WT→VM chimeras were adoptively transferred to naive Rag1-deficient secondary hosts, they trafficked to the lung and recruited neutrophils. Overall, these findings indicated that VM expression by radioresistant cells promoted the activation of autoreactive B cells and T cells that then differentiated into potentially pathogenic effector subsets.

Authors

Kevin MingJie Gao, Kristy Chiang, Sharon Subramanian, Xihui Yin, Paul J. Utz, Kerstin Nündel, Kate A. Fitzgerald, Ann Marshak-Rothstein

×

Figure 4

T lymphocyte recruitment and activation in VM ILD requires a diverse repertoire.

Options: View larger image (or click on image) Download as PowerPoint
T lymphocyte recruitment and activation in VM ILD requires a diverse rep...
(A) Six-week-old sex-matched CD45.1/.1 WT and VM littermates were lethally irradiated and reconstituted with a mixture of BM stem cells comprised of 20% WT CD45.1/.2, 40% OT-I Rag2–/– CD45.2/.2, and 40% OT-II Rag2–/– CD45.2/.2 donor BM. WT+OT-I/-II→WT (n = 4–10) and WT+OT-I/-II→VM (n = 4–8) chimeric mice were evaluated 8–9 weeks later. (B) Percentage of OT-I/-II donor-derived cells within the donor-derived CD45+ BM compartment, CD45+ thymus, CD3+TCRb+ splenic T cells, and CD3+ TCRb+ lung extravascular (EV) T cells. (C) Total number of lung EV T cells derived from either the WT or OT-I/-II donors in WT and VM hosts. (D–G) Percentage of CD44–CD62L+ naive T cells and percentage of CD44+CD62L– effector T cells within lung EV T cells, percentage of CD127+CD69– CD4 effector memory cells within CD4+ lung EV T cells, and percentage of PD-1+CD69+ CD8 PD-1 effector cells within CD8+ lung EV T cells derived from WT and OT-I/-II donors in WT and VM hosts. (H–K) Percentage of naive and effector T cells in splenic T cells, percentage of CD4 effector memory T cells within CD4+ splenic T cells, and percentage of CD8 PD-1 effector cells within CD8+ splenic T cells derived from WT and OT-I/-II donors in WT and VM hosts. For C–K, data points in columns 1 and 2 represent paired WT and OT-I/-II donors from a shared WT host. Similarly, data points in columns 3 and 4 represent paired WT and OT-I/-II donors from a shared VM host. To determine statistical significance, nonparametric Mann-Whitney U tests were used for pair-wise comparisons between columns 1 and 3 and between columns 2 and 4. A Wilcoxon matched pairs signed rank test was used for pairwise comparisons between columns 3 and 4. Statistical significance in B was determined using a multiple Mann-Whitney U test with FDR correction (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts